ADX-038
- Generic Name
- ADX-038
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Phase 1
Recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- ADARx Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05876312
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, London, United Kingdom
🇦🇺Nucleus Network Brisbane, Brisbane, Queensland, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath